Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study for Patients From Prior Genentech/Roche Trials
jRCT2031230279Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of ipatasertib, tiragolumab and atezolizumab in cancer, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s) and Number and Severity of Participants With Selected Adverse Events (NCI CTCAE v5.0). Started Aug 2023; status: recruiting.
02
Drugs
ipatasertibtiragolumabatezolizumab
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2031230279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230279.